CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $269,480 | -19.7% | 5,937 | -0.7% | 0.16% | -19.0% |
| Q2 2023 | $335,605 | +18.4% | 5,978 | -4.6% | 0.20% | +11.4% |
| Q1 2023 | $283,411 | +9.6% | 6,266 | -1.5% | 0.18% | +12.2% |
| Q4 2022 | $258,697 | -46.2% | 6,364 | -13.5% | 0.16% | -67.6% |
| Q3 2022 | $481,000 | +2.1% | 7,353 | -5.1% | 0.48% | +3.7% |
| Q2 2022 | $471,000 | -6.2% | 7,750 | +17.1% | 0.46% | +22.4% |
| Q4 2021 | $502,000 | -14.6% | 6,619 | +26.1% | 0.38% | -13.7% |
| Q3 2021 | $588,000 | -21.7% | 5,251 | +3.5% | 0.44% | -19.0% |
| Q2 2021 | $751,000 | -16.8% | 5,073 | -32.9% | 0.54% | -22.8% |
| Q1 2021 | $903,000 | -47.4% | 7,559 | -32.5% | 0.70% | -46.1% |
| Q4 2020 | $1,716,000 | – | 11,206 | – | 1.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |